FOR IMMEDIATE RELEASE
20th June 2019
Paola - Malta
Malta Enterprise approves CPTM’s application for production of medical cannabis and related research
Cannapharm Technologies Malta Limited (“CPTM” or the “Company”) has today signed a Letter of Intent (LOI) from Malta Enterprise (the “Corporation”) confirming that it has approved CPTM’s application for the setting up in Malta of an operation for the production of medical cannabis in the form of pills, capsules, soluble powder, nasal spray, creams and ointments and related research.
“We are delighted to have received this LOI ”, said Bruce H. Gaston, Director of CPTM. “This is the first step in our application for a cannabis production licence in Malta, allowing CPTM to conduct research, cultivate and process cannabis for medical use. Malta is strategically positioned within Europe and, more importantly, the centre of a well-established pharmaceutical manufacturing industry with a wealth of expertise.”
Seed-to-pharma operation, including research, cultivation and processing into finished doses of various delivery methods
CPTM will be allocated industrial land of around 5,000 m2 for the development of the facility by Malta Industrial Parks Ltd (MIPL)
The facility will be designed in cooperation with local architects and engineers
The production operations will be completed to EU GMP standards
The size and design of the facility will be determined shortly and the facility will be equipped with the latest cultivation, processing and security equipment
CPTM will serve the domestic Maltese, as well as other export markets
Bruce H. Gaston
Cannapharm Technologies Malta Limited (CPTM) is a limited company, registered under the Companies Act, 1995 of the Republic of Malta.
CPTM believes in long-term, incremental growth, based on the latest technological advances. It works closely with governments, regulatory authorities and local municipalities, to utilise, integrate and grow existing local infrastructures, within the framework of regional and governmental development programs and targets.
As an EU-based enterprise, CPTM adheres to and implements the strictest of standards in its productions, whilst maintaining a result-driven, qualitative approach to its pharmaceutical operations in Europe and Asia.